PureTech Health plc (PTCHF)
OTCMKTS
· Delayed Price · Currency is USD
1.670
0.00 (0.00%)
Jan 21, 2025, 3:00 PM EST
PureTech Health Revenue
PureTech Health had revenue of $288.00K in the half year ending June 30, 2024, a decrease of -95.90%. This brings the company's revenue in the last twelve months to $468.00K, down -96.01% year-over-year. In the year 2023, PureTech Health had annual revenue of $3.33M, down -78.68%.
Revenue (ttm)
468.00K
Revenue Growth
-96.01%
P/S Ratio
n/a
Revenue / Employee
5.20K
Employees
90
Market Cap
406.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
PureTech Health News
- 13 days ago - Zentalis Pharmaceuticals and PureTech Health get Fast Track Designation from FDA for their cancer treatments - Seeking Alpha
- 13 days ago - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) - Business Wire
- 16 days ago - PureTech Appoints UBS as UK Corporate Broker - Business Wire
- 5 weeks ago - Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
- 5 weeks ago - PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial - Business Wire
- 6 weeks ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 - Business Wire
- 6 weeks ago - PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting - Business Wire
- 2 months ago - PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors - Business Wire